Ceryvyn Therapeutics Limited CYVNY
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 300.00 | 300.00 | 300.00 |
| Total Other Revenue | -- | -- | -- | -- | -4.20K |
| Total Revenue | 0.00 | 0.00 | 300.00 | 300.00 | -3.80K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | 0.00 | 300.00 | 300.00 | -3.80K |
| SG&A Expenses | 1.36M | 1.33M | 1.91M | 1.90M | 7.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 58.60K | 57.30K | -- | -- | 592.20K |
| Total Operating Expenses | 1.73M | 1.70M | 2.32M | 2.31M | 35.42M |
| Operating Income | -1.73M | -1.70M | -2.32M | -2.31M | -35.42M |
| Income Before Tax | -3.45M | -3.38M | 111.57M | 111.21M | -16.50M |
| Income Tax Expenses | -95.10K | -93.00K | 19.40K | 19.30K | -472.40K |
| Earnings from Continuing Operations | -3.36M | -3.28M | 111.55M | 111.19M | -16.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.36M | -3.28M | 111.55M | 111.19M | -16.02M |
| EBIT | -1.73M | -1.70M | -2.32M | -2.31M | -35.42M |
| EBITDA | -1.73M | -1.69M | -2.32M | -2.31M | -35.42M |
| EPS Basic | 0.00 | 0.00 | 0.08 | 0.08 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.05 | 0.05 | -0.01 |
| EPS Diluted | 0.00 | 0.00 | 0.08 | 0.08 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.05 | 0.05 | -0.01 |
| Average Basic Shares Outstanding | 1.37B | 1.37B | 1.33B | 1.33B | 1.23B |
| Average Diluted Shares Outstanding | 1.37B | 1.37B | 1.33B | 1.33B | 1.23B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |